In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1832 News Items found
Jack Georgakis is seen wrestling in a martial arts class.
FDA Approves Adding Durvalumab Immunotherapy to Prevent Stomach and Esophageal Cancer Recurrence

Learn about a new approach helping to reduce the risk of stomach and esophageal cancer coming back after surgery, which has been approved by the FDA thanks to a clinical trial with immunotherapy led by researchers at MSK.
MSK patient Karren Tyler poses in front of a portrait of two dogs
Able To Speak After Tongue Cancer, Thanks to a Second Opinion at MSK and a Partial Glossectomy

Thanks to a second opinion and minimally invasive surgery at MSK to remove tongue cancer, Karren Tyler is back home in Charlottesville, Virginia, cancer free and focused on giving back to other cancer patients.
Dr. Charles Rudin
FDA Grants Full Approval to Lung Cancer Drug Tarlatamab Based on Trial Led by MSK Researcher

The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK.
Feature
Man with gray hair sits in a doctor's office looking worried
How To Stop the Fear of Cancer

Learn more about five essential strategies for coping with the fear of cancer, from MSK psychiatrist Dr. Monique James.
Lab coat with the MSK logo hangs in a lab
MSK Research Highlights, November 20, 2025

New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.
A researcher points to cells on a screen
Memorial Sloan Kettering Cancer Center Applauds Highly Cited Researchers 2025

In 2025, MSK was again ranked among the top organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers, published by the Institute for Scientific Information at Clarivate.
Microscope in foreground. GSK Graduate Students in the background.
Training Tomorrow’s Leaders: Graduate Education at GSK

Since its founding 19 years ago, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences has attracted bright minds drawn to its connection to MSK. Learn more about how we're training tomorrow's leaders.
Clinical Social Worker Barbara Mitchell is seen smiling.
Talking About a Lung Cancer Diagnosis With Family, Friends, and Others

Learn how to talk about your lung cancer diagnosis with family, friends and others — including questions about smoking.
hematopoietic stem and progenitor cells
MSK Researchers Make Strides Against VEXAS Syndrome

VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments.
A researcher working in an MSK lab
MSK Research Highlights, October 31, 2025

New MSK research uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based system could help head-and-neck cancer survivors report their concerns; and finds adding immunotherapy can boost the effectiveness for hard-to-treat follicular lymphomas.